Beyond probiotics: what the Parkinson’s gut science actually supports

Richard Moore
3 days ago
24 min read

In the first article, the focus was the science. Parkinson’s disease has a real and measurable relationship with the gut microbiome, the trillions of bacteria and other microbes that live in the gut. That relationship shows up in gastrointestinal symptoms that often appear early, a vagus nerve route between belly and brain, abnormal α-synuclein, a protein that can misfold and build up in Parkinson’s, in gut tissue before diagnosis, recurring changes in which gut microbes are present and what they appear able to do, and immune signalling, meaning chemical messages that influence inflammation and immune activity (de Castro Fonseca et al., 2026; Menozzi et al., 2026; Pfeiffer et al., 2024; Wallen et al., 2022).

This second article moves from the biological “how might this work?” question to daily life: bowel habits, food choices, fibre, fermented foods, probiotics, prebiotics, levodopa response, weight, the mouth, and the commercial microbiome tests that often promise more than the evidence can support.

The aim is to explain the evidence, not to give a one-size-fits-all plan. This article does not tell anyone what to eat, drink or take. It describes what the Parkinson’s-and-microbiome literature actually shows, where the evidence is strong, where it is thin, and where it is overstated.

Three boundaries are worth stating before going further.

First, diet, lifestyle and the gut microbiome have not been shown to cure Parkinson’s disease. No diet, probiotic, prebiotic, supplement or commercial protocol has been demonstrated to stop or reverse it. Second, nothing here replaces specialist neurological care. Third, no part of this article asks anyone to carry responsibility for an illness they did not cause. Parkinson’s is not a disease that people give themselves through diet or microbiome neglect (de Castro Fonseca et al., 2026; Tosefsky et al., 2024).

Two questions that often get mixed up

There are two different questions about diet, the gut microbiome and Parkinson’s that often get tangled together.

The first is the big one: can diet or microbiome treatment slow Parkinson’s itself, prevent it, or change the underlying disease process? At the moment, the evidence is not strong enough to say yes. Careful current reviews do not identify any diet, probiotic, prebiotic or microbiome-based intervention that meets the standard needed to recommend it as a disease-modifying treatment, meaning a treatment that changes the underlying course of Parkinson’s rather than only helping symptoms (de Castro Fonseca et al., 2026; Hor et al., 2024; Tosefsky et al., 2024).

The second question is more practical: can gut-focused nutrition help with the problems many people actually live with, such as constipation, food tolerance, inflammation, nutrient intake and medication absorption? Here, the evidence is richer and more useful.

Most of what follows sits inside that second question.

Keeping the two questions separate prevents the common overclaim: promising disease modification from evidence that actually shows gut-symptom improvement, microbiome change or association.

Mediterranean-style eating: useful pattern, not proof

The strongest available diet-pattern data in Parkinson’s come from studies that have followed people over time and measured how closely their diets match Mediterranean-style or MIND-style (Mediterranean-DASH Intervention for Neurodegenerative Delay) eating patterns. A Mediterranean-style pattern usually emphasises vegetables, fruit, legumes, whole grains, olive oil, fish and modest dairy, with lower intake of red meat and ultra-processed foods. The MIND diet is closely related but places extra emphasis on foods such as leafy greens, berries and nuts (Knight et al., 2022; Tosefsky et al., 2024).

Three findings are worth knowing.

Maraki et al. (2019) found that higher Mediterranean diet adherence was associated with a lower probability of meeting criteria for prodromal Parkinson’s, meaning early features that may appear before the classic movement symptoms lead to a diagnosis, including constipation. Maraki et al. (2023), following the same population over time, found that people whose diets more closely matched the Mediterranean pattern at the start of the study had a lower future risk of being diagnosed with Parkinson’s or dementia with Lewy bodies, a related condition involving abnormal α-synuclein build-up and symptoms affecting thinking, movement and alertness. Molsberry et al. (2020), in two large American cohorts totalling 47,679 people, found that higher Mediterranean and Alternative Healthy Eating Index scores were inversely associated with prodromal features, including constipation. Metcalfe-Roach et al. (2021) also reported that closer adherence to MIND or Mediterranean dietary patterns was associated with later age of Parkinson’s onset.

These are important observations, but they are not proof that diet prevents Parkinson’s or slows progression once Parkinson’s has developed. Diet studies are often limited by self-report and by the difficulty of separating diet from other factors that may travel with diet, such as exercise, income, education, smoking, sleep, healthcare access and wider health habits (Tosefsky et al., 2024).

The gut-microbiome relevance is more specific. Mediterranean-style dietary patterns supply fibre, plant diversity and polyphenols, which are plant compounds found in foods such as colourful fruit, vegetables, olive oil, tea and cocoa. These inputs are used by gut bacteria, including short-chain-fatty-acid-producing bacteria often found to be lower in Parkinson’s. Short-chain fatty acids are small compounds made when gut bacteria ferment certain fibres. They help nourish the bowel lining and influence immune activity. The names of these bacteria, such as Faecalibacterium, Roseburia and members of the Lachnospiraceae family, matter less than the job they do: they are linked with fibre fermentation and short-chain fatty acid production (Jackson et al., 2019; Kwon et al., 2024; Wallen et al., 2022; Yoon et al., 2024).

Western-style dietary patterns, by contrast, have been associated with microbial and inflammatory patterns that overlap with some findings described in Parkinson’s microbiome research, including higher exposure to lipopolysaccharide-producing bacteria. Lipopolysaccharide is a molecule from the outer wall of certain bacteria that can trigger immune alarm signals when it interacts with the immune system (Jackson et al., 2019; Zapała et al., 2022).

A cautious conclusion is this: Mediterranean-style eating appears to provide many of the inputs, fibre, polyphenols and plant diversity, that support the microbial functions often found to be depleted in Parkinson’s. That does not prove it slows Parkinson’s, but it gives the dietary pattern biological relevance to the Parkinson’s gut.

The PRIME study protocol, meaning the published plan for a trial whose results are not yet available, was published in 2026. It is important because it shows where the field is going. It is the first multicentre randomised trial designed specifically to test whether a combined Mediterranean diet and physical-activity intervention can shift the gut microbiome and disease-progression markers in people with Parkinson’s (Fognani et al., 2026). Its results are not yet in, so it should not be treated as evidence of benefit. It is a sign that researchers are now testing the diet-microbiome-Parkinson’s link more directly.

A pattern of eating is also more useful than a list of “superfoods” because the gut microbiome responds to overall ecology, not to single ingredients. You cannot redecorate a forest with one bottle of yoghurt.

Fibre and the Parkinson’s microbiome

Fibre matters in Parkinson’s for two gut-microbiome reasons.

First, it is the raw material that many short-chain-fatty-acid-producing bacteria feed on. These are the bacteria repeatedly found to be lower in Parkinson’s microbiome studies (Wallen et al., 2022; Nishiwaki et al., 2024). Second, fibre changes stool bulk and bowel transit, meaning how easily stool moves through the bowel, in a population where constipation is one of the earliest and most common non-motor symptoms (Pfeiffer et al., 2024).

In Parkinson’s-specific data, higher fibre intake has been associated with greater abundance of butyrate-producing bacteria, including Butyricicoccus and Coprococcus. Again, the names are less important than the function: these bacteria are linked with fibre fermentation and short-chain fatty acid production. Higher fibre intake was also linked with lower predicted bacterial production of lipopolysaccharide, the bacterial-wall molecule that can trigger immune alarm signals (Kwon et al., 2024).

In a proof-of-concept trial, Hall et al. (2023) tested a 10-day prebiotic fibre cocktail in 20 people with Parkinson’s. Prebiotic fibres are fibres that feed beneficial gut bacteria already present in the gut. The intervention was well tolerated, increased measured short-chain fatty acid production and shifted selected inflammatory markers, meaning blood or stool signs linked with inflammation. The study was small, not blinded and did not include a placebo comparison group. It is useful for designing better trials, but not strong enough to prove benefit.

Hegelmaier et al. (2020), in a different Parkinson’s-specific intervention, found that a 14-day vegetarian diet including eggs and dairy, with or without bowel cleansing, was associated with gut microbiome shifts and improvement in a standard clinical scale used to measure Parkinson’s motor symptoms at one-year follow-up. The study was small and not a conventional randomised controlled trial, but it remains one of the few intervention studies to pair a defined dietary change with both microbiome and clinical readouts in Parkinson’s.

The practical point is not “add as much fibre as possible.” A slowly moving Parkinson’s gut can react badly to a sudden fibre increase, especially if fluid intake is low. The image to hold is throwing dry leaves into a slow river: the river needs more water before more leaves help.

The 2024 consensus practice recommendations for gastrointestinal dysfunction in Parkinson’s recognise gradual fibre increase, hydration and physical activity as foundational strategies, with osmotic laxatives, medicines that draw water into the bowel to soften stool, such as macrogol, also known as polyethylene glycol, used when constipation does not respond to those measures (Pfeiffer et al., 2024).

Resistant starch: The 2026 study worth watching

One of the most interesting recent Parkinson’s diet-and-microbiome studies tested resistant starch, a fermentable carbohydrate that reaches the colon and can be used by gut bacteria. Resistant starch is found naturally in foods such as cooled cooked potatoes, cooled rice, oats, legumes and some green banana products.

In a randomised controlled trial, a study design where participants are assigned to different groups so researchers can compare effects more fairly, Petrov et al. (2026) studied 74 people with Parkinson’s. The researchers reported that resistant starch changed the gut microbiome, increased Faecalibacterium and short-chain fatty acids, reduced some bacteria that can become problematic when the gut ecosystem is disturbed, and was linked with improvements in Parkinson’s symptoms and inflammatory markers.

This is not proof that resistant starch slows Parkinson’s progression. The trial is still relatively small, and the findings need replication in larger and longer studies. But it is important because it moves the field beyond observation. Instead of only asking whether the Parkinson’s microbiome is different, it asks whether a specific dietary substrate can shift that microbiome in a measurable direction.

For readers, resistant starch is also a useful concept because it sits between “ordinary food” and “microbiome intervention.” However, the specific trial design should not be translated into self-treatment without clinical context.

The careful message is this: resistant starch is not a Parkinson’s treatment, but the 2026 trial makes fibre fermentation one of the more interesting practical areas in Parkinson’s microbiome research (Petrov et al., 2026).

Polyphenols and fermented Foods: where the evidence gets stretched

Polyphenol-rich foods feature in Mediterranean dietary patterns and are often promoted as “brain protective.” In Parkinson’s-microbiome research, the more careful claim is narrower.

Polyphenols may be relevant partly because gut bacteria metabolise them, meaning break them down and transform them, into smaller compounds that can influence inflammation and gut barrier biology. Gut barrier biology refers to how tightly the gut lining controls what passes through it. Some of the bacteria involved overlap with the short-chain-fatty-acid-producing bacteria often reported as depleted in Parkinson’s (Jackson et al., 2019; Tosefsky et al., 2024).

That does not mean high-dose polyphenol supplements have been shown to modify Parkinson’s disease. Parkinson’s-specific human trial evidence for isolated polyphenol supplements, such as resveratrol capsules or green-tea-extract capsules, remains limited, and current Parkinson’s nutrition reviews do not support recommending high-dose antioxidant or polyphenol supplements as disease-modifying strategies (Hor et al., 2024; Tosefsky et al., 2024).

The food pattern has more support than the capsule sold for the purpose.

Fermented foods raise a similar issue. Yoghurt, kefir, sauerkraut, kimchi, miso and kombucha contain live microbes and sit within a broader general-microbiome literature. But Parkinson’s-specific human trials of fermented foods, as distinct from specific probiotic strains and formulas tested in trials, are essentially absent (Hor et al., 2024).

For many people, fermented foods may be reasonable as part of a varied dietary pattern. Claims that they “rewire the gut-brain axis” in Parkinson’s are not supported by Parkinson’s-specific evidence.

Probiotics: The strongest signal we have, and the narrowest one

This is the area where Parkinson’s-specific randomised controlled trials genuinely exist, and where they say something useful but limited.

The most consistent signal is constipation relief, not disease modification.

Probiotic strains are best thought of as cast members in a play. You cannot swap one actor for another and assume the same role will be performed. A study testing Lacticaseibacillus paracasei strain Shirota tells you very little about a different strain, dose or formulation.

Across Parkinson’s-specific trials, specific probiotic or synbiotic preparations, meaning products that combine probiotics with prebiotic fibres, have improved bowel-movement frequency, stool consistency and some gastrointestinal or non-motor symptoms over short periods, usually four weeks to three months. Cereda et al. (2016), in a 120-person Italian randomised controlled trial, found that a fermented milk containing multiple probiotic strains and prebiotic fibre increased complete bowel movements compared with placebo over four weeks. Tan et al. (2021), in a Malaysian double-blind randomised trial of 72 people with Parkinson’s, found that a multi-strain probiotic improved bowel-movement frequency, stool consistency and quality of life over four weeks. Sun et al. (2022), in a Chinese trial of a specific Bifidobacterium probiotic strain called Probio-M8 added to standard Parkinson’s treatment over three months, reported improvements in sleep, anxiety and some gastrointestinal symptoms.

Xie et al. (2022), pooling twelve randomised studies, concluded that probiotics modestly increase bowel-movement frequency and improve stool consistency in Parkinson’s-related constipation.

The pattern is clear enough to be clinically interesting: short-term benefit for constipation and selected non-motor symptoms; some shifts in the gut microbiome; no demonstration that Parkinson’s disease progression itself is altered (Hor et al., 2024; Tosefsky et al., 2024).

Probiotics are also not risk-free for everyone. The consensus practice recommendations flag caution in people with a weakened immune system, including some people taking immune-suppressing medicines, people with severe gut barrier compromise, and people with central venous catheters, meaning long-term medical lines placed into large veins (Pfeiffer et al., 2024).

Prebiotics: feeding the bacteria already there

Prebiotics are different from probiotics. Rather than introducing new bacteria, they are non-digestible fibres that feed bacteria already present in the gut.

The image to hold is fertiliser, not seeds. Prebiotics feed the part of the Parkinson’s inner forest that may be doing useful work, especially the short-chain-fatty-acid-producing bacteria whose depletion is one of the most reproducible Parkinson’s microbiome findings (Romano et al., 2021; Wallen et al., 2022; Nishiwaki et al., 2024).

The Hall et al. (2023) trial described above is the most relevant Parkinson’s-specific prebiotic evidence and was framed by its authors as proof-of-concept for further placebo-controlled trials. The resistant starch trial by Petrov et al. (2026) adds to this direction by testing a fermentable carbohydrate that can alter the gut microbial environment.

The most defensible reading of the current Parkinson’s literature is that prebiotic fibres and fermentable carbohydrates are biologically plausible, clinically relevant to constipation, and worth studying. They are not yet evidence of disease modification (Tosefsky et al., 2024).

Faecal Microbiota Transplant: still experimental

Faecal microbiota transplantation means transferring a screened donor’s gut microbiome into another person’s gut. It has been tested in Parkinson’s because the underlying idea is straightforward: if the Parkinson’s gut microbiome is altered, perhaps replacing or reshaping it could help.

The two best randomised trials do not give the same answer.

GUT-PARFECT, an early-stage Belgian clinical trial of 46 people with mild-to-moderate Parkinson’s, found a modest motor benefit at 12 months in the donor faecal microbiota transplantation arm compared with a placebo transplant made from the person’s own stool (Bruggeman et al., 2024). A Finnish trial by Scheperjans et al. (2024), published in JAMA Neurology in 47 patients, showed that faecal microbiota transplantation was safe and shifted the Parkinson’s microbiome in the expected direction, but did not produce clinically meaningful improvements over placebo on the outcomes the researchers had chosen before the trial began.

Both trials were small and used different protocols. Faecal microbiota transplantation is not a Parkinson’s treatment at present. It is a research intervention being tested in clinical trials. It is not currently recommended outside clinical trials (Hor et al., 2024; Tosefsky et al., 2024).

Why the same Levodopa dose can feel different day to day

This is where gut science becomes immediately practical.

Levodopa, the main medication used to support dopamine signalling in Parkinson’s, is absorbed in the small intestine using a transport system it shares with amino acids from dietary protein. The image to hold is two people trying to push through the same revolving door at the same time. If the door is busy with amino acids from a recent protein-rich meal, less levodopa may get through, and what does get through may reach the brain more slowly (Boelens Keun et al., 2021; Leta et al., 2023).

This is not strictly a microbiome problem, but it sits inside a wider gut story. If the stomach empties slowly, if protein competes with levodopa, or if gut bacteria chemically alter levodopa before it is absorbed, the same dose can behave very differently from one person to another.

The microbiome side of that story has become more detailed. Specific gut bacteria can chemically convert levodopa into dopamine before it reaches the brain. Put more simply, some bacteria can alter levodopa in the gut, wasting part of the dose before it has the chance to work in the nervous system. Maini Rekdal et al. (2019) and van Kessel et al. (2019) identified a bacterial enzyme from Enterococcus faecalis as a major contributor. Van Kessel et al. (2025) showed in a Parkinson’s cohort that stool levels of the relevant bacterial gene were associated with variation in how the body absorbs and processes levodopa between patients.

There is no routine clinical test that yet uses this information. But the mechanism helps explain why two people on similar levodopa doses can have very different responses.

The wider Parkinson’s-gastrointestinal landscape also shapes levodopa absorption. Delayed stomach emptying, which is common in Parkinson’s, can slow and flatten the levodopa peak (Leta et al., 2023). Helicobacter pylori, often shortened to H. pylori, is a common stomach bacterium that can cause ulcers in some people. It can worsen stomach emptying and chemically interfere with levodopa in the stomach; in infected patients, eradication has been associated with improved levodopa response (Leta et al., 2023). Small intestinal bacterial overgrowth, meaning an excess of bacteria in the upper gut, has also been associated with worse levodopa response in Parkinson’s (Leta et al., 2023).

Protein redistribution means shifting most protein to the evening meal and keeping daytime meals lower in protein around levodopa doses. In a systematic review, Boelens Keun et al. (2021) found that this approach can reduce motor fluctuations, meaning changes in how well movement symptoms respond between medication doses, in people who already experience fluctuating medication response. But this is not appropriate for everyone. The 2024 consensus practice recommendations caution that protein redistribution should not reduce total protein below what an older person with Parkinson’s needs for muscle maintenance and frailty prevention. Frailty means reduced strength, resilience and ability to recover from illness or stress (Pfeiffer et al., 2024).

This conversation belongs in clinic, especially when motor fluctuations, weight loss, frailty or swallowing problems are present. The relevant point for this article is that the Parkinson’s gut and its microbiome are both part of why levodopa response varies, and why nutritional decisions in Parkinson’s interact with medication in a way they do not in many other chronic conditions.

Hydration, movement and the constipated gut

The microbiome of the Parkinson’s gut does not float in space. It lives in a physical environment shaped by water, bowel movement and rhythm.

First, slower movement of stool through the colon itself reshapes the microbiome. Slowed transit favours certain bacteria over others. Constipation is independently associated with depletion of bacteria involved in fibre fermentation and short-chain fatty acid production, the same broad group repeatedly identified as depleted in Parkinson’s gut studies (Wallen et al., 2022; Nishiwaki et al., 2024). Part of what is interpreted in the literature as “the Parkinson’s microbiome” may also be the microbiome of the constipated Parkinson’s gut.

Adequate hydration is one of the foundational inputs recommended for managing constipation in Parkinson’s (Pfeiffer et al., 2024). Without enough fluid, increasing fibre can worsen bloating or discomfort.

Second, physical activity affects bowel movement and is included alongside fibre and fluid in the foundational management of Parkinson’s gastrointestinal dysfunction (Pfeiffer et al., 2024). The PRIME study is designed to test whether a combined Mediterranean diet and physical-activity intervention can shift both the gut microbiome and Parkinson’s outcomes, but results are not yet available (Fognani et al., 2026).

Third, sleep and circadian rhythm, the body’s internal day-night clock, may influence gut symptoms, although the microbiome link in Parkinson’s remains less certain. Poor sleep can aggravate daytime gut symptoms in Parkinson’s, but whether this works through microbiome rhythms in Parkinson’s specifically remains unresolved (Pfeiffer et al., 2024).

When eating less makes the gut problem harder

Unintentional weight loss is more common in Parkinson’s than many people realise. A recent review reported that malnutrition and malnutrition risk are clinically important concerns in Parkinson’s care (Tosefsky et al., 2024). The drivers are often gut-related or food-intake related: reduced appetite, delayed stomach emptying, nausea, swallowing difficulty, the energy cost of motor symptoms and the practical work of preparing food when movement is more difficult (Pfeiffer et al., 2024).

The link back to the microbiome is direct. A Parkinson’s gut taking in less food, less variety and less fibre loses many of the inputs that short-chain-fatty-acid-producing bacteria depend on. Reduced food variety may therefore worsen the very microbial ecology that Parkinson’s microbiome studies suggest is already under pressure (Kwon et al., 2024; Wallen et al., 2022).

In practice, protecting food intake may sometimes matter more than adding extra fibre or probiotics. For someone losing weight, struggling to swallow or eating very little, the priority is not a perfect microbiome diet. It is safe, adequate and realistic nourishment.

The nutrient consideration most often raised in the Parkinson’s-medication context is that long-term levodopa metabolism can be associated with raised homocysteine and with low vitamin B12 and folate in some patients. Homocysteine is a blood marker linked to methylation, a set of chemical reactions involved in processes such as nerve function and vitamin B12 and folate metabolism. This does not mean everyone on levodopa needs supplements, but it supports monitoring and individualised assessment (Pfeiffer et al., 2024).

The mouth, the oral microbiome and the Parkinson’s gut

The oral microbiome, the community of microbes living in the mouth, may sound like a detour, but it is part of the same digestive tract. Oral bacteria are swallowed continuously, and Parkinson’s-related changes in chewing, saliva, swallowing and oral hygiene may alter the microbial traffic entering the gut.

Zapała et al. (2022), comparing the oral microbiome of 59 people with Parkinson’s to 108 healthy controls, found a Parkinson’s-distinct oral microbiome profile. They also reported that diet preferences, including a more Western-style intake, correlated with this profile.

The clinical layer matters. People with Parkinson’s can be at increased risk of oral health problems because of reduced facial movement, drooling, swallowing difficulty, dry mouth, medication effects and reduced dexterity for brushing. Poor oral health can make chewing harder, which may reduce food variety, which may then affect both nutritional intake and microbial diversity. Significant swallowing difficulty also increases the risk of aspiration pneumonia, a serious chest infection that can happen when food, drink or saliva enters the lungs (Pfeiffer et al., 2024).

The point is not that the oral microbiome explains Parkinson’s. It is that in Parkinson’s, the mouth and gut are part of one digestive ecosystem, shaped by chewing, swallowing, saliva, food variety and oral hygiene.

Commercial microbiome tests: interesting, not diagnostic

Blog one covered why stool microbiome testing is not currently a validated way to diagnose Parkinson’s or predict who will develop it.

For this article, the practical point is different: a commercial microbiome report, meaning a stool test sold directly to the public, should not be used to prescribe a Parkinson’s supplement protocol, claim disease reversal, or replace clinical assessment. Research-grade microbiome models remain exploratory, and current Parkinson’s nutrition reviews do not endorse direct-to-consumer microbiome testing for Parkinson’s care (Hor et al., 2024; Lubomski et al., 2022; Tosefsky et al., 2024).

A stool test may be interesting. It is not yet a clinical map for Parkinson’s nutrition.

What researchers are testing next

The next few years are likely to clarify five areas.

First, larger and longer Parkinson’s-specific dietary intervention trials. The PRIME study protocol is the first multicentre randomised trial testing whether a Mediterranean diet and physical-activity intervention affects the Parkinson’s gut microbiome and disease-progression markers (Fognani et al., 2026). It is not evidence of benefit yet, but it reflects a more mature research direction.

Second, more precise mapping of the prodromal Parkinson’s microbiome. Cross-sectional data, meaning snapshots taken at one point in time, already suggest that a Parkinson’s-like microbiome signature can be detected in people at genetic or prodromal risk (Huang et al., 2023; Menozzi et al., 2026). Longitudinal follow-up, where people are followed over time, will be needed to clarify who progresses and who does not.

Third, better tools to detect gut α-synuclein pathology directly. Seed amplification assay technology, a laboratory method that can detect tiny amounts of misfolded α-synuclein by seeing whether they “seed” further misfolding, has detected pathological α-synuclein activity in stomach biopsies from some people with early Parkinson’s, although it is not yet a routine clinical tool (Shin et al., 2025).

Fourth, refinement of microbiome-targeted interventions. The two existing randomised Parkinson’s faecal microbiota transplantation trials disagree, but their differences may help future trials improve donor selection, route of administration, repeat dosing and the integration of gut barrier and inflammation measures (Bruggeman et al., 2024; de Castro Fonseca et al., 2026; Scheperjans et al., 2024).

Fifth, microbiome-aware levodopa pharmacology. This means future strategies that consider how gut bacteria may affect levodopa absorption and processing. The bacterial levodopa-metabolism pathway identified by Maini Rekdal et al. (2019) and van Kessel et al. (2019), and translated into Parkinson’s patients by van Kessel et al. (2025), is a plausible candidate for future microbiome-aware medication strategies. It is not yet ready to guide routine clinical decisions.

None of this requires anyone living with Parkinson’s now to wait for perfect evidence before receiving gut support. It does, however, set realistic expectations. The strongest advances are coming from carefully designed clinical studies, not from the wellness market.

What this means in real life

The truthful version of the Parkinson’s-and-gut story is more interesting than the loud one.

The gut is part of Parkinson’s: in symptoms, in mechanism, in medication response, in nutritional resilience and in quality of life. Nutritional resilience means maintaining enough energy, protein and key nutrients despite appetite, digestion or swallowing challenges. The microbiome is part of how that involvement may play out. None of that means Parkinson’s is caused by what someone ate or by the bacteria in their gut, and none of it means any current diet, probiotic, prebiotic, supplement or commercial protocol stops or reverses the disease.

With reasonable confidence, the evidence supports five practical conclusions.

Mediterranean-style dietary patterns are associated with lower prodromal Parkinson’s probability and may support a more favourable gut microbial environment, but they are not proven disease-modifying treatment (Maraki et al., 2019, 2023; Metcalfe-Roach et al., 2021; Molsberry et al., 2020; Tosefsky et al., 2024).

Defined probiotics can modestly improve Parkinson’s-related constipation in the short term, but they have not been shown to modify the disease (Cereda et al., 2016; Hor et al., 2024; Sun et al., 2022; Tan et al., 2021; Xie et al., 2022).

Prebiotic fibre, resistant starch and some dietary interventions can shift the Parkinson’s microbiome in early trials, but larger and longer studies are needed before they can be translated into disease-modification claims (Hall et al., 2023; Hegelmaier et al., 2020; Petrov et al., 2026; Tosefsky et al., 2024).

Levodopa response is shaped by gut motility, protein timing, stomach factors and bacterial enzymes, which makes medication-aware nutrition especially important in Parkinson’s care (Boelens Keun et al., 2021; Leta et al., 2023; Maini Rekdal et al., 2019; van Kessel et al., 2019, 2025).

Oral health, swallowing, appetite and food variety may influence both nutritional status and the gut microbial environment, especially in people at risk of weight loss or malnutrition (Pfeiffer et al., 2024; Tosefsky et al., 2024; Zapała et al., 2022).

The evidence points to something less dramatic, but more useful. For most people living with Parkinson’s, the gut-microbiome work is not about chasing a cure through supplements or commercial stool tests. It is about understanding constipation, food tolerance, medication timing, weight loss, swallowing, fibre, hydration and the daily realities that shape quality of life.

The Parkinson’s gut and its microbiome are worth understanding well, not because they offer a shortcut, but because they sit close to the realities people live with every day: bowels, meals, medication timing, energy, swallowing, weight, sleep and dignity.

Support for Parkinson’s Disease at You Nutrition Clinic

At You Nutrition Clinic, we specialise in nutrition and lifestyle support for neurological diseases and disorders, including Parkinson’s disease and Parkinsonism.

Our Parkinson’s disease specialist, Melody, is a BANT registered Nutritionist and CNHC registered Nutritional Therapy Practitioner, with a BSc in Psychology, an MSc in Personalised Nutrition and a three-year DipION from the Institute for Optimum Nutrition.

With a focus on gastrointestinal health and the gut-brain axis, Melody supports people with symptoms, a diagnosis, or risk of Parkinsonism. She helps clients optimise nutrient intake around medication use, support neurological function, improve quality of life, and better understand the relationship between diet, digestion and brain chemistry.

To find out more or enquire about personalised Parkinson’s nutrition support, contact admin@younutritionclinic.com.

🧩 Connect with us

For research updates, practical tips, and ongoing inspiration, follow us on Instagram:

👉 @nutritionandthebrain

👉 @younutritionkids

Stay curious. Stay hopeful. Support your brain. 🧠

Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult with a qualified, registered medical doctor (MD) for diagnosis and treatment decisions.

References

Boelens Keun, J. T., Arnoldussen, I. A. C., Vriend, C., & van de Rest, O. (2021). Dietary approaches to improve efficacy and control side effects of levodopa therapy in Parkinson’s disease: A systematic review. Advances in Nutrition, 12(6), 2265–2287. https://doi.org/10.1093/advances/nmab060

Bruggeman, A., Vandendriessche, C., Crozier, T. W. M., De Pue, A., Vanwynsberghe, J., Spincemaille, S., De Decker, M., et al. (2024). Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson’s disease (GUT-PARFECT): A double-blind, placebo-controlled, randomised, phase 2 trial. eClinicalMedicine, 71, 102563. https://doi.org/10.1016/j.eclinm.2024.102563

Cereda, E., Bonvecchio, A., Iorio, L., Cilia, R., Akpalu, A., Cham, M., Cassani, E., Pezzoli, G., & Barichella, M. (2016). Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT. Neurology, 87(12), 1274–1280. https://doi.org/10.1212/WNL.0000000000003127

de Castro Fonseca, M., Zanetti, L., Fanourakis, S., Sulzer, D. L., & Mazmanian, S. K. (2026). The gut microbiome, systemic inflammation, and autoimmunity in Parkinson’s disease. The Lancet Neurology, 25(1), 103–114. https://doi.org/10.1016/S1474-4422(25)00382-5

Fognani, A., Rotondo, R., Savo Sardaro, M. L., de Iure, A., Gaglione, M., Casali, M., Leonardi, L., Radicati, F. G., Vacca, L., Guescini, M., Donati Zeppa, S., Gatta, L., Stocchi, F., Picconi, B., & De Pandis, M. F. (2026). Effects of combined Mediterranean diet and physical activity intervention on the gut microbiome and disease progression in individuals with Parkinson’s disease: Study protocol for a multicenter, randomized controlled pilot study (PRIME study). Frontiers in Aging Neuroscience, 18, 1743490. https://doi.org/10.3389/fnagi.2026.1743490

Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., Chen, T., Manfready, R., Ouyang, B., Rasmussen, H. E., Sedghi, S., Goetz, C. G., & Keshavarzian, A. (2023). An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants. Nature Communications, 14, 926. https://doi.org/10.1038/s41467-023-36497-x

Hegelmaier, T., Lebbing, M., Duscha, A., Tomaske, L., Tönges, L., Holm, J. B., Nielsen, H. B., Gatermann, S. G., Przuntek, H., & Haghikia, A. (2020). Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson’s disease. Cells, 9(2), 376. https://doi.org/10.3390/cells9020376

Hor, J. W., Toh, T. S., Lim, S.-Y., & Tan, A. H. (2024). Advice to people with Parkinson’s in my clinic: Probiotics and prebiotics. Journal of Parkinson’s Disease, 14(7), 1271–1281. https://doi.org/10.3233/JPD-240172

Huang, B., Chau, S. W. H., Liu, Y., Chan, J. W. Y., Wang, J., Ma, S. L., Lam, S. P., et al. (2023). Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives. Nature Communications, 14, 2501. https://doi.org/10.1038/s41467-023-38248-4

Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019). Diet in Parkinson’s disease: Critical role for the microbiome. Frontiers in Neurology, 10, 1245. https://doi.org/10.3389/fneur.2019.01245

Knight, E., Geetha, T., Burnett, D., & Babu, J. R. (2022). The role of diet and dietary patterns in Parkinson’s disease. Nutrients, 14(21), 4472. https://doi.org/10.3390/nu14214472

Kwon, D., Zhang, K., Paul, K. C., Folle, A. D., Del Rosario, I., Jacobs, J. P., Keener, A. M., Bronstein, J. M., & Ritz, B. (2024). Diet and the gut microbiome in patients with Parkinson’s disease. npj Parkinson’s Disease, 10, 89. https://doi.org/10.1038/s41531-024-00681-7

Leta, V., Klingelhoefer, L., Longardner, K., Campagnolo, M., Levent, H. Ç., Aureli, F., Metta, V., Bhidayasiri, R., Chung-Faye, G., Falup-Pecurariu, C., Stocchi, F., Jenner, P., Warnecke, T., Ray Chaudhuri, K., & on behalf of the International Parkinson’s Disease Non-Motor Study Group. (2023). Gastrointestinal barriers to levodopa transport and absorption in Parkinson’s disease. European Journal of Neurology, 30(5), 1465–1480. https://doi.org/10.1111/ene.15734

Lubomski, M., Xu, X., Holmes, A. J., Muller, S., Yang, J. Y. H., Davis, R. L., & Sue, C. M. (2022). Nutritional intake and gut microbiome composition predict Parkinson’s disease. Frontiers in Aging Neuroscience, 14, 881872. https://doi.org/10.3389/fnagi.2022.881872

Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019). Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science, 364(6445), eaau6323. https://doi.org/10.1126/science.aau6323

Maraki, M. I., Yannakoulia, M., Stamelou, M., Stefanis, L., Xiromerisiou, G., Kosmidis, M. H., Dardiotis, E., Hadjigeorgiou, G. M., Sakka, P., Anastasiou, C. A., Simopoulou, E., & Scarmeas, N. (2019). Mediterranean diet adherence is related to reduced probability of prodromal Parkinson’s disease. Movement Disorders, 34(1), 48–57. https://doi.org/10.1002/mds.27489

Maraki, M. I., Yannakoulia, M., Stamelou, M., Stefanis, L., Xiromerisiou, G., Kosmidis, M. H., Dardiotis, E., Hadjigeorgiou, G. M., Sakka, P., Scarmeas, N., & Anastasiou, C. A. (2023). Mediterranean diet is associated with a lower probability of prodromal Parkinson’s disease and risk for Parkinson’s disease/dementia with Lewy bodies: A longitudinal study. European Journal of Neurology, 30(4), 934–942. https://doi.org/10.1111/ene.15698

Menozzi, E., Ren, Y., Geiger, M., Schapira, A. H. V., Ehrlich, S. D., Meslier, V., et al. (2026). Microbiome signature of Parkinson’s disease in healthy and genetically at-risk individuals. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-026-04318-5

Metcalfe-Roach, A., Yu, A. C., Golz, E., Cirstea, M., Sundvick, K., Kliger, D., Foulger, L. H., Mackenzie, M., Finlay, B. B., & Appel-Cresswell, S. (2021). MIND and Mediterranean diets associated with later onset of Parkinson’s disease. Movement Disorders, 36(4), 977–984. https://doi.org/10.1002/mds.28464

Molsberry, S., Bjornevik, K., Hughes, K. C., Healy, B., Schwarzschild, M., & Ascherio, A. (2020). Diet pattern and prodromal features of Parkinson disease. Neurology, 95(15), e2095–e2108. https://doi.org/10.1212/WNL.0000000000010523

Nishiwaki, H., Ito, M., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Yoshida, T., Hanada, H., Takeuchi, I., Katsuno, M., & Hirayama, M. (2024). Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease. npj Parkinson’s Disease, 10, 106. https://doi.org/10.1038/s41531-024-00724-z

Petrov, V. A., Schade, S., Laczny, C. C., Hällqvist, J., May, P., Jäger, C., Aho, V. T. E., Hickl, O., Halder, R., Lang, E., Caussin, J., Lebrun, L. A., Schulz, J., Unger, M. M., Mills, K., Mollenhauer, B., & Wilmes, P. (2026). Resistant starch improves Parkinson’s disease symptoms through restructuring of the gut microbiome and modulating inflammation. Brain, Behavior, and Immunity, 132, 106217. https://doi.org/10.1016/j.bbi.2025.106217

Pfeiffer, R. F., Isaacson, S. H., & Pahwa, R. (2024). Consensus practice recommendations for management of gastrointestinal dysfunction in Parkinson disease. Parkinsonism & Related Disorders, 124, 106982. https://doi.org/10.1016/j.parkreldis.2024.106982

Romano, S., Savva, G. M., Bedarf, J. R., Charles, I. G., Hildebrand, F., & Narbad, A. (2021). Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. npj Parkinson’s Disease, 7, 27. https://doi.org/10.1038/s41531-021-00156-z

Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P. A. B., Smolander, O.-P., Aho, V. T. E., Vetkas, N., Toivio, L., Kainulainen, V., Fedorova, T. D., Lahtinen, P., Ortiz, R., Kaasinen, V., Satokari, R., & Arkkila, P. (2024). Fecal microbiota transplantation for treatment of Parkinson disease: A randomized clinical trial. JAMA Neurology, 81(9), 925–938. https://doi.org/10.1001/jamaneurol.2024.2305

Shin, C., Im, J. P., Han, J.-Y., et al. (2025). Cognitive function correlates with gastric alpha-synuclein seeding activity in early Parkinson’s disease. npj Parkinson’s Disease, 11, 311. https://doi.org/10.1038/s41531-025-01152-3

Sun, H., Zhao, F., Liu, Y., Ma, T., Jin, H., Quan, K., Leng, B., Zhao, J., Yuan, X., Li, Z., Li, F., Kwok, L.-Y., Zhang, S., Sun, Z., Zhang, J., & Zhang, H. (2022). Probiotics synergized with conventional regimen in managing Parkinson’s disease. npj Parkinson’s Disease, 8, 62. https://doi.org/10.1038/s41531-022-00327-6

Tan, A. H., Lim, S.-Y., Chong, K. K., A. Manap, M. A. A., Hor, J. W., Lim, J. L., Low, S. C., Chong, C. W., Mahadeva, S., & Lang, A. E. (2021). Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study. Neurology, 96(5), e772–e782. https://doi.org/10.1212/WNL.0000000000010998

Tosefsky, K. N., Zhu, J., Wang, Y. N., Lam, J. S. T., Cammalleri, A., & Appel-Cresswell, S. (2024). The role of diet in Parkinson’s disease. Journal of Parkinson’s Disease, 14(s1), S21–S34. https://doi.org/10.3233/JPD-230264

van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019). Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nature Communications, 10, 310. https://doi.org/10.1038/s41467-019-08294-y

van Kessel, S. P., Auvinen, P., Scheperjans, F., & El Aidy, S. (2025). Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease. npj Parkinson’s Disease, 11, 84. https://doi.org/10.1038/s41531-025-00903-6

Wallen, Z. D., Demirkan, A., Twa, G., Cohen, G., Dean, M. N., Standaert, D. G., Sampson, T. R., & Payami, H. (2022). Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nature Communications, 13, 6958. https://doi.org/10.1038/s41467-022-34667-x

Xie, L., Chen, D., Zhu, X., & Cheng, C. (2022). Efficacy and safety of probiotics in Parkinson’s constipation: A systematic review and meta-analysis. Frontiers in Pharmacology, 13, 1007654. https://doi.org/10.3389/fphar.2022.1007654

Yoon, H. J., Kang, W., Jo, S., Hwang, Y. S., Lee, J. H., Chung, S. J., & Park, Y. K. (2024). Dietary quality and the gut microbiome in early-stage Parkinson’s disease patients. Nutritional Neuroscience, 27(7), 754–767. https://doi.org/10.1080/1028415X.2023.2253025

Zapała, B., Stefura, T., Milewicz, T., Wątor, J., Piwowar, M., Wójcik-Pędziwiatr, M., Doręgowska, M., Dudek, A., Jania, Z., & Rudzińska-Bar, M. (2022). The role of the Western diet and oral microbiota in Parkinson’s disease. Nutrients, 14(2),